Apple gets FDA okay to use AFib tool in clinical trials
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
Price cut unlocks NHS use of sickle cell drug Oxbryta
It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after a
Healthcare AI from Cera ‘could save NHS and UK £1bn a year’
An artificial intelligence-powered home healthcare model that aims to keep elderly people out of hospital and residential care and in their own homes would save £1 billion
Boehringer will use Walgreens trials unit for obesity trial
Walgreens’ plans to disrupt the clinical trials sector have taken a step forward with a high-profile partnership with Boehringer Ingelheim.
Novartis digs deeper in radiopharma with $1.75bn Mariana buy
Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Onc
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Final FDA rule on LDTs creates a paradigm shift for laborato...
WASHINGTON, D.C., April 30, 2024 –The Food and Drug Administration’s (FDA) final rule has reclassified laboratory developed tests (LDTs) as medical devices, according to Avalere.
FT US PHARMA AND BIOTECH SUMMIT
2024 is a pivotal year for the US healthcare sector.
4th Next Generation Gene Therapy Vectors Summit 2024
Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), the industry’s only hub for covering the latest advances and innovations in
2nd ADC Toxicity Summit 2024
Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
15th World Bispecific Summit 2024
Radically Optimize Bi, Tri & Multispecific Antibodies to Enhance Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize the Therapeutic Index & Enhance Combi